TNFSF10 and cancer: For example, TRAIL fusions with single chain fragment variable (scFv) antibodies were developed, which target various tumor-specific antigens, which are often overexpressed in cancer, such as EGFR, ErbB2, Ep-CAM, or immune cell antigens, such as CD40, PD-L1, or IL2 receptors, to hasten and reinforce immune responses [3].